Intas Pharmaceuticals, along with its global subsidiaries under the Accord brand, has expanded its leadership in the biosimilar market with the acquisition of UDENYCA (pegfilgrastim-cbqv) from Coherus BioSciences. This strategic move positions Intas as one of the largest global suppliers of pegfilgrastim. UDENYCA, a biosimilar to Neulasta, adds to the growing FDA-approved biosimilar portfolio of both Intas and Accord, further supporting their goal to increase access to high-quality oncology treatments in key international markets.

Health Technology Insights: Turn Therapeutics Intranasal Vaccine Candidate Demonstrates Extended Stability

Accord BioPharma, the U.S. specialty division of Intas, will now oversee the ongoing commercialization of UDENYCA. The product is indicated to help reduce the risk of infection caused by febrile neutropenia in patients with non-myeloid cancers undergoing myelosuppressive chemotherapy. UDENYCA is available in three different administration formats—autoinjector, on-body injector, and prefilled syringe—providing flexibility for patients whether they are at home, traveling, or receiving treatment in a clinical setting. Since its launch, UDENYCA has been used to treat over 300,000 patients, with more than 1.4 million units distributed.

Health Technology Insights: Texas Life Science Forum 2025: Innovators and Investors Unite

This acquisition also brings a skilled team of professionals from Coherus BioSciences into Accord BioPharma. Employees from departments including sales, marketing, finance, supply chain, and manufacturing have joined to help maintain seamless product continuity and ensure consistent support for healthcare providers and patients during the transition and beyond.

Binish Chudgar, Chairman and Managing Director of Intas Pharmaceuticals, said, “We are energized by this addition to Accord BioPharma’s portfolio as it reflects our commitment to improving patient access to high-quality treatments that meet the evolving needs of both patients and healthcare providers.”

Health Technology Insights: Flatiron Health Appoints Nathan Hubbard as Chief Executive Officer

To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com